D. E. Shaw & Co. Inc. Sells 49,834 Shares of AtriCure, Inc. (NASDAQ:ATRC)

D. E. Shaw & Co. Inc. decreased its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 42.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 67,462 shares of the medical device company's stock after selling 49,834 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.14% of AtriCure worth $2,062,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Johnson Financial Group Inc. raised its position in shares of AtriCure by 1,184.1% during the 4th quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company's stock valued at $49,000 after acquiring an additional 1,492 shares during the last quarter. Heck Capital Advisors LLC bought a new stake in shares of AtriCure during the 4th quarter valued at $60,000. Venturi Wealth Management LLC raised its position in shares of AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock valued at $69,000 after acquiring an additional 2,100 shares during the last quarter. KBC Group NV raised its position in shares of AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock valued at $72,000 after acquiring an additional 932 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of AtriCure by 232.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,871 shares of the medical device company's stock valued at $88,000 after acquiring an additional 2,008 shares during the last quarter. Institutional investors own 99.11% of the company's stock.

Insider Transactions at AtriCure

In related news, Director Karen Prange sold 6,100 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares in the company, valued at approximately $679,603.36. This trade represents a 25.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 3.50% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on the stock. JMP Securities reiterated a "market outperform" rating and set a $60.00 target price on shares of AtriCure in a research report on Wednesday, April 30th. Stifel Nicolaus upped their price objective on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Canaccord Genuity Group lowered their price objective on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research report on Friday, March 28th. Oppenheimer upped their price objective on shares of AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a research report on Thursday, March 27th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $50.67.

AtriCure Stock Down 0.3%

Shares of AtriCure stock traded down $0.10 during trading hours on Friday, reaching $32.71. 330,069 shares of the company's stock were exchanged, compared to its average volume of 652,208. The company has a 50 day moving average of $32.40 and a two-hundred day moving average of $34.84. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $43.11. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.62 billion, a P/E ratio of -34.43 and a beta of 1.57.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The medical device company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.11. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. The company had revenue of $123.62 million during the quarter, compared to the consensus estimate of $122.92 million. During the same period in the prior year, the business posted ($0.28) EPS. The company's quarterly revenue was up 13.5% on a year-over-year basis. On average, sell-side analysts forecast that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.